Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nohla Therapeutics

Request full access

Developing an shelf alternative to bone marrow transplants

Seattle, United StatesFounded 2015Biotech & Life Sciences

About Nohla Therapeutics

Nohla Therapeutics, founded in 2015 by Dr. Colleen Delaney, operated as a clinical-stage cellular therapy company focused on developing off-the-shelf treatments for patients with critical hematological diseases. The company was established as a spin-out from the Fred Hutchinson Cancer Research Center to commercialize a technology platform developed over two decades. Dr. Delaney, a physician-scientist with a background from Harvard Medical School and extensive research at Fred Hutch, pioneered the methods for making umbilical cord blood transplants more successful and widely available. Her work led to the creation of a proprietary platform that expands the number of stem and progenitor cells from umbilical cord blood donations by up to 500 times.

The company's core business revolved around this ex vivo umbilical cord blood expansion platform, which creates universal donor cellular therapies. These therapies were designed to be used on-demand without the need for Human Leukocyte Antigen (HLA) matching, providing a significant advantage over traditional bone marrow transplants that require a close biological match. The business model focused on advancing its lead product candidates through clinical trials to gain regulatory approval and then commercialize them. Its primary clients were patients with life-threatening hematological malignancies, such as acute myeloid leukemia (AML), who were undergoing intensive chemotherapy. The company's lead product, known as dilanubicel (NLA101), was an expanded hematopoietic stem and progenitor cell therapy. It was developed to provide a temporary bridge of infection-fighting cells, promoting rapid hematopoietic recovery and reducing the risk of infection while the patient's own immune system recovered post-treatment.

Throughout its operation, Nohla Therapeutics achieved several milestones. The company launched in late 2015, securing a 20-year exclusive licensing agreement with the Fred Hutchinson Cancer Research Center and raising significant initial funding. It successfully raised a total of $120 million over four funding rounds, with its Series A in 2016 bringing in $43.5 million and a Series B round in 2018 totaling $56 million from investors including ARCH Venture Partners, Fidelity, and Celgene. The company advanced its lead product, dilanubicel, into multiple Phase 2 clinical trials for applications in allogeneic transplant and AML. In early 2017, Kathleen Fanning, a biotech executive with over 30 years of experience, was appointed President and CEO to guide the company through clinical development and manufacturing ramp-up. Despite its progress, the company ceased operations in late 2019. Following her time at Nohla, Dr. Delaney founded Deverra Therapeutics in 2020 to continue her work in cellular immunotherapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
58.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Risk Management, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jul 2018 $11M $44M Premier Partners · Schroder Adveq · UTEC - The University of Tokyo Edge Capital Partners —
SERIES BOther financing May 2018 $45M $180M 5AM Ventures · ARCH Venture Partners · Celgene · AML Partners —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Nohla Therapeutics website traffic

Latest recorded traffic for Nohla Therapeutics is 50 monthly website visits. Nohla Therapeutics's team grew 0% over the past year.

Latest monthly visits50 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nohla Therapeutics in the Seattle ecosystem

Live from Dealroom

The Nohla Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • ARCH Venture Partners
  • 5AM Ventures
  • Fidelity Investments
  • Bristol-Myers Squibb
  • Celgene
  • AML Partners
  • Alexandria Venture Investments
  • Schroder Adveq
  • UTEC - The University of Tokyo Edge Capital Partners
  • Premier Partners

Other known investors1 additional known investor

  • Fred Hutchinson Cancer Research Center
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Seattle HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nohla Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nohla Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.